People with spinal-cord injury and other neurological conditions need intensive gait rehabilitation, but many robotic systems are heavy and costly.
R&D Focus
Powered rehabilitation exoskeletons, backdrivable actuators and gait-control software.
Innovative Solution
ABLE Exoskeleton is an adjustable powered hip-knee system designed for clinical gait rehabilitation with a lightweight, user-centered architecture.
Solution Effectiveness
By 2023, the company reported testing with more than 200 people with spinal-cord injury and more than 400,000 assisted steps. These figures show use and validation, not a comparative clinical outcome.
Investment Funding
Last Funding Stage
Grant
Total Funding Amount
$2.52M
Last Funding Amount
$65.4K
Last Funding Date
04-01-2021
Startup Stage
Early Stage
Lead Investors
Grifols, Ship2B, MassRobotics, EIT Health, Blue Goose Capital
People
Founders
Alfons Carnicero
Alex Farreny
Josep Llagunes
CEO
Alfons Carnicero
About
Able Human Motion is a developer of a robotic exoskeletons technology intended to improve the quality of life of people with disabilities
Products
Product
ABLE Exoskeleton for clinical neurorehabilitation.
Star Product
ABLE Exoskeleton, because it is the company’s first CE-marked commercial device.
Demo Product or Complete Product?
Commercial clinical product in the European Union; first sales followed CE marking in 2024.
Future Plan
Market Expansion
Commercial expansion across European rehabilitation centers; the company is also developing a personal-use version.
Investment Funding
Raised €704,000 in pre-seed funding in 2019 and has received European and national innovation grants for product development.
Awards and Recognitions
Certifications
CE Mark under the EU Medical Device Regulation in April 2024; ISO 13485 quality system certification reported in 2021.
M&A and Collabs
Collab
Clinical centers in Spain and Germany: safety, performance and rehabilitation studies.
Collab
SKYFI: distribution partnership for Poland announced in 2024.
Something missing or incorrect on this page? Help us enrich this information
